Skip to main content

Table 2 Response rates by induction therapy in both treatment cohorts

From: First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study

 

MTX (n = 56)

Teniposide (n = 33)

P value

Complete responsea

28 (50%)

13 (39.4%)

0.182

Partial response

13 (23.2%)

11 (33.3%)

Stable disease

4 (7.1%)

5 (15.2%)

Progressive disease

9 (16.1%)

4 (12.1%)

Died on therapy

2 (3.6%)

0

Overall response

41 (73.2%)

24 (72.7%)

0.627

ORR/IELSG score

 Low risk

12/18 (66.7%)

8/11 (72.7)

 

 Intermediate risk

24/31 (77.4%)

14/20 (70%)

0.467

 High risk

5/7 (71.4%)

2/2 (100%)

 
  1. The seven patients who could not be evaluated for response had insufficient imaging data or available medical records. However, some of these patients could be included in the survival analysis. Data are expressed as n (%) or n/N (%) unless otherwise stated
  2. aComplete response rate and overall response rate (ORR) for both cohorts according to the International Extranodal Lymphoma Study Group (IELSG) risk score[22]. No interaction between treatment cohort and IELSG risk score was detected (P = 0.655)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us